Pembrolizumab (Keytruda) Archives

Tag: Pembrolizumab (Keytruda)

A drug that binds to the protein PD-1 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that express the protein PD-L1, that have certain mutations (changes) in genes involved in DNA repair, or that have a high number of tumor mutations. Pembrolizumab is used alone or with other drugs to treat certain types of skin cancer (squamous cell carcinoma of the skin, Merkel cell carcinoma, and melanoma), colorectal cancer, endometrial cancer, renal cell carcinoma (a type of kidney cancer), esophageal cancer, small cell lung cancer, non-small cell lung cancer, hepatocellular carcinoma (a type of liver cancer), cervical cancer, stomach cancer, gastroesophageal junction cancer, urothelial carcinoma (a type of bladder cancer), Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, head and neck cancer, and other solid tumors. It is also being studied in the treatment of other types of cancer. Pembrolizumab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Keytruda.

25 Sep 2025

By Ronny Allan

8 Comments

Immunotherapy and Neuroendocrine Neoplasms

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Anti-angiogenic therapy, Atezolizumab (Tecentriq), Avelumab (Bavencio), Avistan, Bavencio, Bevacizumab, Cisplatin, Colorectal cancer, DLL3, EGFR, Epidermal growth factor receptor (EGFR), Fluoropyrimidine, Head and Neck Cancer, Hodgkin lymphoma, Immunotherapy, Ipilimumab (Yervoy), Keytruda, Lanreotide, Melanoma, Microsatellite instability-high (MSI-H), Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Nivolumab (Opdivo), Non-small cell lung cancer (NSCLC), Paraganglioma, PD-1/PD-L1 Inhibitors, PDR001, Pembrolizumab (Keytruda), Pemetrexed disodium, Pheochromocytoma, Solid tumour, Squamous cell carcinoma, Tecentriq (Atezolizumab), Tumour mutational burden (TMB), Typical lung NET, Yervoy

Updated 24th September 2025. Introduction There's a lot of Immunotherapy stuff out there! The picture regarding its use in Neuroendocrine Neoplasms is not clear and there is no general roadmap printed. I first heard of Immunotherapy for NETs following attendance at ENETS 2017 in Barcelona. The presentation that sticks out was one given by Dr Matthew Kulke, a well-known NET Specialist in Boston. My reaction to the presentation was one of 'expectation management' and caution i.e. it's too soon to know if we will get any success and when we will get it. He also hinted that it's more likely…

13 Feb 2025

By Ronny Allan

0 Comments

Lanreotide and Keytruda – the PLANET study (NCT03043664)

Clinical Trials and ResearchClinical trial, Immunotherapy, Lanreotide, Pembrolizumab (Keytruda), Somatostatin analogues, Somatuline Autogel (US: depot)

Update 13th February 2025. In my main coverage of Immunotherapy for Neuroendocrine Neoplasms (NENs), you will see a section where one NET specialists described Neuroendocrine Tumours as an “immunological desert”. What was meant by is that there’s little evidence immunotherapy is effective in the majority of Neuroendocrine Tumours (NETs). The output from this trial continues to back that view. It is important to note the nomenclature of NETs rather than NENs as almost all the immunotherapy drug approvals to date have been for Neuroendocrine Carcinomas (NECs). As the trial abstract conclusion said, "We conclude that immune checkpoint blockade had low…

07 Mar 2021

By Ronny Allan

0 Comments

Treatment for Neuroendocrine Cancer – a summary for patients

Treatment5-Fluorouracil (5-FU), Atezolizumab (Tecentriq), Avelumab (Bavencio), Capecitabine (Xeloda), CAPecitabine TEMozolomide (CAPTEM)., Chemotherapy, Cisplatin, Cisplatin/Etoposide, Cryoablation, Cyberknife, Etoposide, External beam radiotherapy, FOLFIRI, FOLFOX, Gamma knife, Interferon alpha (IFNα), Irinotecan (Campto), Irreversible electroporation (IRE), Lanreotide, Liver directed therapy, Lu-177, Lutathera, NanoKnife®, Nivolumab (Opdivo), Octreotide (Octreotide acetate), Opdivo (Nivolumab), Paclitaxel (Taxol), Pembrolizumab (Keytruda), Peptide receptor radionuclide therapy (PRRT), Proton beam therapy, Radiation therapy, Somatostatin analogues, Somatostatin receptors (SSTR), Somatuline Autogel (US: depot), Stereotactic body radiotherapy (SBRT), Stereotactic radiosurgery (SRS), Streptozotocin (Zanosar), Surgery, Targeted therapy, Temozolomide (Temodal), Thorson-Bioerck syndrome, Tumour mutational burden (TMB), Vepesid), Watchful waiting

1. Scope This summary provides an overview of the types of therapy known for treating Neuroendocrine Cancer. They will have been approved at least by one national or regional approval agency, may not be available or approved in your own country; and may appear in clinical guidelines for the treatment of Neuroendocrine Cancer. Clinical trials will not be covered, although it's noted that some of the approved treatments listed may be in follow on trials either to prove new coverage or used in combination with another drug. For a list of clinical trials covered by the author, click here.…

10 Jun 2019

By Ronny Allan

3 Comments

Clinical Trials of PV-10 (Rose Bengal) for the treatment of Neuroendocrine Tumours (NET)

Clinical Trials and ResearchAdvanced neuroendocrine cancer, Immunotherapy, Keytruda, Melanoma, Metastatic Neuroendocrine Cancer, Neuroendocrine neoplasm (NEN), Pembrolizumab (Keytruda), PV-10, Rose Bengal

Reviewed and edited 17th March 2022Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at ENETS Conference 2022Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) (NCT02693067) was presented at the annual conference of the European Neuroendocrine Tumor Society (ENETS), held from March 10-11, 2022 in a hybrid setting in Barcelona, Spain and online.The oral presentation was made…

22 Oct 2015

By Ronny Allan

7 Comments

Your Money or Your Life

Inspiration, Survivorship, TreatmentAlopecia, Chemotherapy, Hodgkin lymphoma, Immunotherapy, Keytruda, Melanoma, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Nivolumab (Opdivo), Opdivo (Nivolumab), Pembrolizumab (Keytruda), Stem Cell

As I have a 2 year old post about Danielle, I wanted to preface it with this message. It is with great sadness that I let you know Danielle Tindle passed away at the end of August 2017 after a prolonged battle with Neuroendocrine Carcinoma. She had been fighting cancer in one form or another for 12 years and became passionate in campaigning for more attention for young cancer patients. I've been following her story for almost 2 years and she has really inspired me. The title of this article is based on the title of a TV programme about…